Format

Send to

Choose Destination
See comment in PubMed Commons below
Leuk Res. 2013 Dec;37(12):1622-7. doi: 10.1016/j.leukres.2013.09.002. Epub 2013 Sep 8.

A phase I study of decitabine and rapamycin in relapsed/refractory AML.

Author information

1
Department of Medicine, Division of Hematology/Oncology, University of Rochester, Rochester, NY 14642, United States. Electronic address: jane_liesveld@urmc.rochester.edu.

Abstract

A phase I study utilizing decitabine (DAC) followed by the mammalian target of rapamycin (mTOR) inhibitor, rapamycin, in patients with relapsed/refractory adult AML was undertaken to assess safety and feasibility. Patients received DAC 20mg/m(2) intravenously daily for 5 days followed by rapamycin from day 6 to day 25 at doses of 2 mg, 4 mg, and 6 mg/day in a standard 3+3 dose escalation design. Twelve patients completed treatment for safety evaluation. Maximum tolerated dose (MTD) was not reached, and except for grade 3 mucositis in 4 patients, no other significant unexpected non-hematologic toxicities have occurred indicating safety of this regimen. This trial is registered at clinical trials.gov as NCT00861874.

KEYWORDS:

AML; Decitabine; Phase I; Rapamycin; Refractory; Relapsed

PMID:
24138944
DOI:
10.1016/j.leukres.2013.09.002
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center